Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis

Abstract Menaquinone‐7 (MK‐7), a form of vitamin K2, supports bone health and prevents arterial calcification. Microbial fermentation for MK‐7 production has attracted widespread attention because of its low cost and short production cycles. However, insufficient substrate supply, unbalanced precursor synthesis, and low catalytic efficiency of key enzymes severely limited the efficiency of MK‐7 synthesis. In this study, utilizing Bacillus subtilis BSAT01 (with an initial MK‐7 titer of 231.0 mg/L) obtained in our previous study, the glycerol metabolism pathway was first enhanced to increase the 3‐deoxy‐arabino‐heptulonate 7‐phosphate (DHAP) supply, which led to an increase in MK‐7 titer to 259.7 mg/L. Subsequently, a combination of knockout strategies predicted by the genome‐scale metabolic model etiBsu1209 was employed to optimize the central carbon metabolism pathway, and the resulting strain showed an increase in MK‐7 production from 259.7 to 318.3 mg/L. Finally, model predictions revealed the methylerythritol phosphate pathway as the major restriction pathway, and the pathway flux was increased by heterologous introduction (Introduction of Dxs derived from Escherichia coli ) and fusion expression (End‐to‐end fusion of two enzymes by a linker peptide), resulting in a strain with a titer of 451.0 mg/L in a shake flask and 474.0 mg/L in a 50‐L bioreactor. This study achieved efficient MK‐7 synthesis in B. subtilis , laying the foundation for large‐scale MK‐7 bioproduction.